The SPARKLE Study evaluates the safety and efficacy of Orviglance in patients with suspected or known liver lesions and severe kidney impairment. The results, originally announced in May 2024, showed that the primary endpoint was successfully met with high statistical significance and demonstrated that the company’s magnetic resonance imaging (MRI) contrast agent, Orviglance significantly improved the visualization of focal liver lesions compared to unenhanced MRI.

The results have been accepted as an oral presentation at the 2024 annual conference of the Radiological Society of North America, the world’s largest radiology conference. The presentation was accepted in the Cutting-Edge Research category and will be presented by Dr. Alvin Silva, SPARKLE Principal Investigator and Professor of Radiology, Mayo Clinic, Phoenix, United States and is co-authored by Dr. Beatrice L. Madrazo, SPARKLE Principal Investigator and Professor of Radiology, University of Miami, United States.

“I am very pleased that the study has been selected as an oral presentation at the prestigious radiology conference, RSNA. The results support the potential clinical value of a novel manganese based liver specific MR contrast alternative for patients with severe kidney disease” said Dr. Beatrice L. Madrazo.

• Title of presentation: SPARKLE: A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of ACE-MBCA in Patients with Known or Suspected Focal Liver Lesions and Severe Renal Impairment
• Timing of presentation: 2 Dec, 13:30-14:00 CDT, local time Chicago